AI Article Synopsis
- New d-ribofuranoside compounds were created by combining isoxazole and triazole or two triazole rings, and these compounds were fully characterized.
- These newly developed derivatives, along with other d-riboside compounds, were tested on PC3 prostate cancer cells, showing significant inhibition of cell growth and causing the cells to stop progressing through the G0/G1 phase of the cell cycle.
- The study found that the effectiveness of these compounds was enhanced when the carbohydrate part was protected with a cyclopentylidene group, rather than an isopropylidene group.
Article Abstract
New d-ribofuranoside derivatives containing two five membered heterocycles, isoxazole and triazole or two triazole rings, were synthesized. The final products as well as the synthetic precursors were physically and spectroscopically characterized. These new diheterocyclic derivatives together with other d-riboside compounds were assessed for their impact on PC3 cell line viability. We found that exposure of prostate cancer cells to some of these compounds caused a significant inhibition of cell growth and a G0/G1 cell cycle arrest, which was concomitant with alterations in the expression of proteins involved in cell cycle progression. Furthermore, the inhibitory activity was improved in di-heterocycles when the carbohydrate moiety was protected with a cyclopentylidene group compared to the isopropylidene analogues.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2014.08.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!